?

Franchini Indrani Lall

EVP, Chief Compliance Officer
Alexion Pharmaceuticals, Inc.
US, Boston [HQ]
CIK 1708764

Data Source

We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.

Latest Information

Shares :
0
Price per Share :
$182.50
Equivalence :
$0.0

Transaction History

  • D
    Form 4
    0.0 Shares After Transaction
    Value : $n/a
    $0.0
    07/21/21
  • Footnotes:
    #1 Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").
  • F
    Form 4
    63,450 Shares After Transaction
    Value : $11,230,650.00
    $164,256.00
    06/08/21
  • A
    Form 4
    64,378 Shares After Transaction
    Value : $n/a
    $0.0
    02/28/21
  • A
    Form 4
    90,262 Shares After Transaction
    Value : $n/a
    $0.0
    07/14/21
  • A
    Form 4
    116,075 Shares After Transaction
    Value : $n/a
    $0.0
    07/14/21

Get PRO Today.

PRO unlocks 3 more insider transactions made by Franchini Indrani Lall

Start Free PRO trial Subscribe to PRO